Rhythm Pharmaceuticals is on the verge of the first approval for rare hypothalamic obesity – a billion-dollar market with little competition. Oral and weekly variants in the pipeline ensure long-term market shares and growth potential. Rhythm Pharmaceuticals (NASDAQ: RYTM) is purposefully advancing into a field that is barely recognized...
The Best Growth Stocks by Revenue Growth
Stocks with high revenue growth on a TTM basis, sorted by distance to the 52-week high.
| Rank | Stock | Price | Rev. Gr. | Dist. 52WH | Perf. 20D |
|---|---|---|---|---|---|
| WKN | Symbol | EPS Growth | Rel. Strength | |||
| 1 | Palomar Holdings | 130.13 $ | 40.22 % | 9.49 % | -0.24 % |
| A2PHB6 | PLMR | 49.48 % | 96 | |||
| 2 | HCI Group | 137.20 $ | 49.16 % | 9.67 % | -1.52 % |
| A1W02H | HCI | 199.39 % | 85 | |||
| 3 | Alignment Healthcare | 18.84 $ | 48.25 % | 10.54 % | 19.92 % |
| A2QSBM | ALHC | - % | 99 | |||
| 4 | HEICO | 187.93 $ | 43.13 % | 14.27 % | -5.63 % |
| 914043 | HEI/A | 19.31 % | 87 | |||
| 5 | Heico | 238.62 $ | 43.13 % | 15.86 % | -5.58 % |
| 889997 | HEI | 19.31 % | 88 | |||
| 6 | StoneX Group | 70.30 $ | 64.14 % | 17.76 % | -3.65 % |
| A2P8CE | SNEX | 7.01 % | 95 | |||
| 7 | Catalyst Pharmaceuticals | 20.86 $ | 32.17 % | 20.27 % | -1.62 % |
| A0LCUL | CPRX | 111.86 % | 90 | |||
| 8 | Newmont | 46.64 $ | 53.66 % | 20.57 % | 6.90 % |
| 853823 | NEM | - % | 83 | |||
| 9 | Rhythm Pharmaceuticals | 53.57 $ | 81.55 % | 21.89 % | 4.38 % |
| A2H5A0 | RYTM | - % | 87 | |||
| 10 | Mercadolibre | 1,842.40 $ | 43.63 % | 22.44 % | -8.13 % |
| A0MYNP | MELI | 43.98 % | 86 | |||
Subscribe now to see the full ranking
Already a subscriber? Login
Sample Issue
$
0
one issue
Bestseller
Trial Subscription
$
33
1 month